President Trump tweeted Jan. 2 he had a “much bigger & more powerful” nuclear button on his desk than Mr. Kim, who reportedly said he keeps a nuclear button on his desk at all times.
Demand for potassium iodide, which protects the thyroid from absorbing radioactive iodine, spiked following the tweet, according to distributor Troy Jones, president of Nukepills.com.
“On Jan. 2, I basically got in a month’s supply of potassium iodide and I sold out in 48 hours,” Mr. Jones told KHN. During that two-day period, he shipped out about 140,000 doses of potassium iodide, compared to his usual 8,400 doses.
Another major potassium iodide supplier, Anbex, also saw an increased demand after the president’s tweet. “We are a wonderful barometer of the level of anxiety in the country,” Anbex President Alan Morris told KHN.
While many Americans are buying potassium iodide over fears of a potential nuclear attack, the FDA and CDC do not recommend solely using potassium iodide as an antidote to such a threat. “KI (potassium iodide) cannot protect the body from radioactive elements other than radioactive iodine — if radioactive iodine is not present, taking KI is not protective and could cause harm,” according to the CDC’s website.
More articles on supply chain:
Mylan reaffirms $1B share buyback plan
FDA: IV fluid shortage exacerbated by hurricane damage to Puerto Rico is expected to improve
Stanford Blood Center faces critical shortage of blood, notes the flu is keeping potential donors away
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
